Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Julien Da Silva, Giuseppe Lepore, Tadej Battelino, Arcelia Arrieta, Javier Castañeda, Benyamin Grossman, John Shin, Ohad Cohen, Julien Da Silva, Giuseppe Lepore, Tadej Battelino, Arcelia Arrieta, Javier Castañeda, Benyamin Grossman, John Shin, Ohad Cohen

Abstract

Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Methods: Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Results: Users (N = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible (N = 812) reduced their GMI by 0.4% ± 0.4% (P = 0.005) and increased their TIR by 12.1% ± 10.5% (P < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, P < 0.0001) and TIR >70% (34.6% vs. 74.9%, P < 0.0001) when compared with pre-AHCL initiation. Conclusion: Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition.

Keywords: Automated insulin delivery; Diabetes; Hyperglycemia; Hypoglycemia; Real-world evidence; Time-in-range.

Conflict of interest statement

G.L. has received research support or advisory board fees from Eli Lilly, Novo Nordisk, Sanofì, AstraZeneca, Boheringer Ingelheim, and Abbott Diabetes Care. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, Indigo, and DreaMed Diabetes. T.B. received honoraria for participating on the speaker's bureau of Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Aventis, Astra Zeneca, and Roche. T.B. owns stocks of DreamMed Diabetes. T.B.'s institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz, and Zealand Pharma. J.D., A.A., J.C., B.G., J.S., and O.C. are employees of Medtronic.

Figures

FIG. 1.
FIG. 1.
MiniMed™ 780G system performance after AHCL initiation, by country. AHCL, advanced hybrid closed loop.
FIG. 2.
FIG. 2.
MiniMed™ 780G system performance pre- and post-AHCL initiation. Glycemic outcomes and time in AHCL are shown for MiniMed™ 780G system users with ≥10 days of SG data pre- and post-AHCL initiation. All differences between pre- and post-AHCL initiation values are statically significant (P < 0.0001 for all, except TBR <54 with P = 0.0005). TBR, time below range; SG, sensor glucose.
FIG. 3.
FIG. 3.
Percentage of users achieving recommended GMI and TIR goals with the MiniMed™ 780G system. Percentage of MiniMed™ 780G users achieving the international recommendations of (A) GMI and >70% for the (B) percentage of time spent between 70 and 180 mg/dL (3.9 and 10.0 mmol/L), after initiating AHCL (black curve), compared with pre-AHCL initiation (gray curve). TIR, time-in-range; GMI, glucose management indicator.

References

    1. Battelino T, Danne T, Bergenstal RM, et al. : Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593–1603.
    1. Runge AS, Kennedy L, Brown AS, et al. : Does time-in-range matter? perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes. Clin Diabetes 2018;36:112–119.
    1. Ranjan AG, Rosenlund SV, Hansen TW, et al. : Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care 2020;43:2882–2885.
    1. Garg SK, Weinzimer SA, Tamborlane WV, et al. : Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2017;19:155–163.
    1. Da Silva J, Arrieta A, Castaneda J, et al. : Real-world Performance of the MiniMed™ 780G System: impact of initiating automated basal and correction boluses. Diabetes Technol Ther 2021;23:A79–A80.
    1. Addala A, Auzanneau M, Miller K, et al. : A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care 2021;44:133–140.
    1. Holman N, Knighton P, Kar P, et al. : Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020;8:823–833.
    1. Renard E, Ikegami H, Daher Vianna AG, et al. : The SAGE study: global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes Metab Res Rev 2020:e3430.
    1. Leelarathna L, Choudhary P, Wilmot EG, et al. : Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes Metab 2021;23:655–660.
    1. Weisman A, Bai JW, Cardinez M, et al. : Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:501–512.
    1. Carlson AL, Bode BW, Brazg RL, et al. : Safety and glycemic outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in subjects with T1D. Anders L. Carlson, Jennifer L. Sherr, Dorothy I. Shulman, Satish K. Garg, et al.:Safety and glycemic outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in subjects with T1D Technology & Therapeutics. [ahead of print].
    1. Collyns OJ, Meier RA, Betts ZL, et al. : Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 2021;44:969–975.
    1. Bergenstal RM, Beck RW, Close KL, et al. : Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018;41:2275–2280.
    1. Riddlesworth TD, Beck RW, Gal RL, et al. : Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther 2018;20:314–316.
    1. Blonde L, Khunti K, Harris SB, et al. : Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 2018;35:1763–1774.
    1. Ioannidis JP, Haidich AB, Pappa M, et al. : Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821–830.
    1. Monti S, Grosso V, Todoerti M, et al. : Randomized controlled trials and real-World data: differences and similarities to Untangle Literature Data. Rheumatology (Oxford) 2018;57(57 Suppl 7):vii54-vii58.
    1. Elliott L, Fidler C, Ditchfield A, et al. : Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther 2016;7:45–60.
    1. American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S73–S84.
    1. Foster NC, Beck RW, Miller KM, et al. : State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther 2019;21:66–72.
    1. Bergenstal RM, Nimri R, Beck RW, et al. : A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 2021;397:208–219.
    1. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. : Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther 2021;23:342–349.
    1. Brown SA, Kovatchev BP, Raghinaru D, et al. : Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707–1717.
    1. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther 2021;23:601–608.
    1. Habif S, Singh H, Manning M, et al. : Quality of life outcomes and glycemic control from the T:slim X2 Pump with Control-IQ Technology—Real World Observations from the CLIO Study. Diabetes Technol Ther 2021;23:A-66.
    1. Da Silva J, Velado K, Agrawal P, et al. : Real-life use and performance of the MiniMed™ 670G System in Europe. Diabetes Technol Ther 2020;22:A96–A97.
    1. Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A, et al. : Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2021;9:609–615.
    1. Petrovski G, Al Khalaf F, Campbell J, et al. : One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol 2021;58:207–213.
    1. Shin J, Chen X, Liu M, et al. : Robust Glycemic Effects of MiniMed™ Advanced Hybrid Closed-Loop (AHCL) System regardless of existing therapy. Diabetes 2021;70(Supplement 1):706-P.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj